OrbusNeich
 | |
| Company type | Public |
|---|---|
| HKEX: 6929 | |
| Industry | Medical Instruments & Supplies |
| Founded | 2000 |
| Headquarters | Hong Kong |
Key people | Teddy Chien (Founder), David Chien (Chairman and CEO), Denise Lau (COO) |
| Products | Stent, balloon |
Number of employees | 500+ |
| Website | orbusneich |
OrbusNeich Medical Group Holdings Limited (OrbusNeich) (/ˌɔːrbəsˈniːʃ/ or-bəs-NEESH) is a company that designs, develops, manufactures and markets medical devices for the treatment of vascular diseases.[1]
In 2013, OrbusNeich received CE mark for the world's first and only dual therapy stent, the COMBO Dual Therapy Stent. The COMBO Stent features active endothelial progenitor cell (EPC) capture technology, which promotes the accelerated natural healing of the vessel wall after the implantation of a stent.[2] Several trials including a randomized study dedicated to patients with Acute Coronary Syndrome (ACS) and registries with a sizeable ACS patient subset demonstrated consistently low event rates and short DAPT option of 3 months, if needed.[3][4][5]
History
[edit]Neich Medical, with its headquarters in Hong Kong, China, established its manufacturing facilities in Shenzhen, China, in 2000 to begin the research and development of interventional medical devices, including balloon catheters.[6]
By 2001, the company had obtained license approval for the sale of its first balloon catheter product in China and the European Union markets. Other balloon catheters soon followed.
Neich Medical continued its international expansion in 2005 by acquiring its longstanding partner Orbus Medical Technologies Inc., a company with strong ties in the European medical community, whose main business was the research and development of interventional medical devices, pioneering the design of the dual helical coronary stent platform, thus forming OrbusNeich Medical.
Over the years, OrbusNeich has brought to market a range of stent and balloon devices, including a series of angioplasty balloon catheters for the management of the most complex lesions, including chronic total occlusion, for both the treatment of coronary and peripheral vascular disease.
In addition to PCI/PTA balloons and coronary stent products, the company is actively expanding into neuro-vascular intervention and structural heart disease areas.[citation needed]
Products
[edit]OrbusNeich owns more than 180 granted patents globally.
Locations
[edit]OrbusNeich is represented throughout the world. The Corporate Headquarters are located in Hong Kong, and direct sales teams are operating from Hong Kong, Singapore, Malaysia, Japan, PRC, Germany, Switzerland, Spain and France. A distributor network is covering more than 70 countries across six continents. The company has a production and research & development facility in Shenzhen, China, an advanced research & development facility in Fort Lauderdale, Florida, USA and further production facilities in Hoevelaken, The Netherlands.[citation needed]
References
[edit]- ^ (January 2010). "OrbusNeich, a company providing stent technology for the future." European Heart Journal.
- ^ S. Saito, HARMONEE Study, European Heart Journal, April 2018.
- ^ G. de Luca et al, REDUCE Study, EuroIntervention, August 2019.
- ^ L.S. Kerkmeijer et al. Catheterization & Cardiovascular Interventions, October 2020.
- ^ M. Haude et al., REMEDEE Trial, JACC: Cardiovascular Interventions, April 2013.
- ^ "About Us - OrbusNeich".